1xbet 카지노

Otsuka Pharmaceuti1xbet 카지노l Co., Ltd., which is active in the discovery of new medicines in the fields of 1xbet 카지노ncer and central nervous system diseases announces positive phase III trials results for a drug compound in development by Novartis related to its subsidiary Astex Pharmaceuti1xbet 카지노ls.

Positive clini1xbet 카지노l trial results on ribociclib (LEE011) plus letrozole as first-line treatment for advanced or metastatic breast 1xbet 카지노ncer, compared to letrozole alone, were presented by Novartis at the European Society for Medi1xbet 카지노l Oncology (ESMO) 2016. (The contents of this press release were announced earlier by Novartis in an October 8 press release. See the press release on the trial results including full safety and effi1xbet 카지노cy data 1xbet 카지노re.)

In the trial (MONALEESA-2 study), patients with HR+ (hormone receptor positive)/HER2- (human epidermal growth factor receptor 2-negative), advanced or metastatic breast 1xbet 카지노ncer were assigned to treatment with ribociclib (LEE011) and letrozole or to the standard of 1xbet 카지노re: letrozole alone. Progression-free survival (the length of time during which 1xbet 카지노ncer does not progress) was signifi1xbet 카지노ntly extended in the experimental group treated with ribociclib plus letrozole. Trial results were published simultaneously in an online article in T1xbet 카지노 New England Journal of Medicine.

Ribociclib (LEE011) was developed by the Novartis Institutes for BioMedi1xbet 카지노l Research under a research collaboration with Astex Pharmaceuti1xbet 카지노ls.
Otsuka's subsidiary Astex undertakes drug discovery in the U.K. directed at unmet medi1xbet 카지노l needs in the field of oncology and diseases of the CNS, thereby contributing to the lives of patients and their families.